Influenza Vaccine Clinical Trial
Official title:
Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial
In this open label, single centre, pilot randomized controlled clinical trial the investigators aim to compare the immunogenicity and safety of a new influenza vaccination strategy consisting in the topical administration of imiquimod at the injection site before vaccination vs. a standard intramuscular vaccine injection in SOT recipients and HIV-infected individuals. The investigators planned to enroll 70 outpatients patients (50% solid-organ transplant recipients and 50% HIV-infected patients) regularly followed at the Transplantation center and the Infectious disease outpatients' clinics of the Lausanne University Hospital. Study participants will be randomized in a 1:1:1 ratio to receive the standard intramuscular vaccine (control group) or a topical application of an imiquimod containing cream followed by intramuscular (imiquimod-IM) or intradermal (imiquimod-ID) vaccine injection. After vaccination participants will be followed for a period of 180 days. Blood samples will be drawn at baseline and at day 21 and 180 for assessment of immunogenicity. Safety outcomes will be assessed immediately after vaccine administration, and at day 7 (phone call), 21 and 180.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03285997 -
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age
|
Phase 3 | |
| Recruiting |
NCT05996549 -
Cost-effectiveness of the Influenza Vaccination
|
Phase 4 | |
| Completed |
NCT04546854 -
Influenza 2020/2021
|
N/A | |
| Completed |
NCT05157425 -
Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination
|
N/A | |
| Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
| Completed |
NCT01180699 -
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients
|
N/A | |
| Completed |
NCT00760175 -
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients
|
N/A | |
| Completed |
NCT00542776 -
Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine
|
N/A | |
| Completed |
NCT06304038 -
Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
|
||
| Recruiting |
NCT04086628 -
Influenza Vaccine in Children With Asthma
|
||
| Completed |
NCT00828555 -
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
|
N/A | |
| Completed |
NCT04230343 -
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
|
N/A | |
| Recruiting |
NCT03399357 -
Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial
|
N/A | |
| Completed |
NCT02153671 -
Immunogenicity of H5N1 Vaccine Following H5N2
|
Phase 2 | |
| Completed |
NCT00461981 -
A Phase 2 Study to Evaluate Immune Responses of FluMist®
|
Phase 2 | |
| Recruiting |
NCT05070494 -
Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT04785794 -
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
|
Phase 1 | |
| Completed |
NCT05163847 -
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
|
Phase 1 | |
| Not yet recruiting |
NCT04355806 -
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
|
||
| Completed |
NCT01368796 -
Comparison of 4 Influenza Vaccines in Seniors
|
Phase 4 |